Alyeska Investment Group’s Aligos Therapeutics ALGS Stock Holding History

Alyeska Investment Group’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.06M	Hold	412,000	–	–	0.01%	526
2025 Q4	$3.84M	Hold	412,000	–	–	0.01%	483
2025 Q3	$4.04M	Hold	412,000	–	–	0.01%	470
2025 Q2	$2.97M	Hold	412,000	–	–	0.01%	466
2025 Q1	$3.4M	Buy	+412,000	New	+$9.03M	0.01%	389
2024 Q3	–	Sell	-11,369	Closed	-$99.5K	–	520
2024 Q2	$99.5K	Buy	+11,369	New	+$200K	﹤0.01%	540
2024 Q1	–	Sell	-115,289	Closed	-$2.3M	–	455
2023 Q4	$1.91M	Buy	+115,289	New	+$1.98M	0.01%	375
2021 Q2	–	Sell	-600	Closed	-$341K	–	701
2021 Q1	$341K	Hold	600	–	–	﹤0.01%	692
2020 Q4	$415K	Buy	+600	New	+$292K	0.01%	456

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Alyeska Investment Group's ALGS Position: Q1 2026 in Review

Alyeska Investment Group held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 412,000 shares worth $3.06M. The position accounts for 0.01% of the portfolio, ranked #526.

Alyeska Investment Group first reported a position in ALGS in Q4 2020 and has held it in 9 quarters since. The position peaked at $4.04M in Q3 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Alyeska Investment Group held 412,000 shares of Aligos Therapeutics worth $3.06M as of Q1 2026.
Alyeska Investment Group left its Aligos Therapeutics share count unchanged in Q1 2026.
Aligos Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #526 holding.
Alyeska Investment Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 9 quarters since.
Alyeska Investment Group's Aligos Therapeutics position peaked at $4.04M in Q3 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.